Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Clinical Trial to Confirm Efficacy and Evaluate Safety of Twice-daily Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adult Subjects With Moderate to Severe Chronic Hand Eczema (DELTA 1)

X
Trial Profile

A Phase 3 Clinical Trial to Confirm Efficacy and Evaluate Safety of Twice-daily Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adult Subjects With Moderate to Severe Chronic Hand Eczema (DELTA 1)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Delgocitinib (Primary)
  • Indications Eczema
  • Focus Registrational; Therapeutic Use
  • Acronyms DELTA 1
  • Sponsors LEO Pharma
  • Most Recent Events

    • 12 Jan 2024 According to a LEO Pharma media release, the company will present safety and efficacy result from this study and pooled data from the DELTA 1 and DELTA 2 at the upcoming Winter Clinical and Maui Derm conferences this month. The 2024 Winter Clinical Conference will take place Jan. 12-17 in Honolulu, Hawaii, while Maui Derm is being held from Jan. 22-26 in Maui, Hawaii.
    • 13 Oct 2023 According to a LEO Pharma media release, pooled analysis data of DELTA 1 & DELTA 2 will be presented at the 32nd European Academy of Dermatology and Venereology (EADV) Congress from the 11th to the 14th of October in Berlin, Germany.
    • 13 Oct 2023 According to a LEO Pharma media release, data from this study will be presented at the 32nd European Academy of Dermatology and Venereology (EADV) Congress from the 11th to the 14th of October in Berlin, Germany.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top